Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
G
229000
vs
K
KOSPI 200
Over the past 12 months, Gencurix Inc has underperformed KOSPI 200, delivering a return of +20% compared to KOSPI 200's +125% growth.
Stocks Performance
229000 vs KOSPI 200
Performance Gap
229000 vs KOSPI 200
Performance By Year
229000 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Gencurix Inc
Glance View
Gencurix is a South Korean molecular diagnostics company that develops and sells gene-based test kits used in hospitals and labs. Its products help doctors detect cancers, infectious diseases, and other medical conditions by analyzing DNA or RNA from patient samples. The company also sells related reagents and assay systems that support these tests in the lab. Its main customers are clinical laboratories, hospitals, and diagnostic service providers that need accurate tests for patient care. Gencurix makes money by selling test kits, reagents, and other consumables that labs use repeatedly, which gives the business a recurring product-sales model rather than a one-time equipment sale. It may also earn revenue from partnerships, technology transfers, and other licensing-related activities tied to its test platforms. What makes Gencurix different is its role at the point where biotechnology meets routine medical testing. It does not treat patients directly; instead, it supplies the tools that let healthcare providers make faster and more precise diagnosis decisions. That puts the company in a specialized part of the healthcare value chain, where product reliability, regulatory clearance, and test performance matter more than branding or store presence.